ZYBERNO
Stock Report
Updated Aug 30, 2026

Veradermics, Inc (MANE)

Healthcare • NYSE

$97.93

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Veradermics, Inc (MANE) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-11.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Veradermics, Inc (MANE) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:97.93
Market Cap:$3.96B

Valuation Multiples (2)

P/B Ratio:4.87x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.64B

Price Action & Momentum (1)

% of 52-Week High:74.6%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:70.53x
Quick Ratio:70.53x
Cash Ratio:27.31x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:813,052,000.00
Cash And Cash Equivalents:319,333,000.00
Long Term Debt:$428.00K
Net Debt:-$318.53M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$72.35M

Bottom Line Performance (3)

-$70.00M
Income Before Tax:-$23.50M
Ebitda Ttm:-72,347,000.00

Operating Expenses (5)

Operating Expenses:29,553,000.00
R And D Expense:18,607,000.00
Sga Expense:10,946,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$825.74M
Current Assets:$824.75M
Ppe Net:41,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:12,122,000.00
Current Liabilities:11,694,000.00
Long Term Debt:$428.00K
Short Term Debt:$379.00K

Equity & Capital (3)

Equity:$813.61M
Retained Earnings:-$174.16M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:5,920,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,516,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$71.60M-$71.63M

Investment Activities (1)

Investing Cash Flow:-$101.30M

Financing Activities (3)

Financing Cash Flow:$269.11M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$1.73

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.77

Book Value & Capital (2)

Book Value Per Share:$20.12
Cash Per Share:7.90

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:MANE
Company Name:Veradermics, Inc
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:40.44M
Shares Outstanding Basic:40.44M
Shares Outstanding Diluted:40.44M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 12:37:46 UTC
Data Timestamp:2026-08-30T12:37:46.798009
Scroll to Top